drugset / Trial / NCT03078478

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

NCT03078478 ↗

Phase 3 Completed 1609 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe and North America. The aim of the trial is to compare the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs. Due to change in glycaemic data collection process, this trial is amended to allow for a full 36 weeks (maintenance 2 period) of the use of the new process.

Timeline

Start
2017-03-13
Primary completion
2019-02-13
Completion
2019-03-04

Outcome

Missed primary endpoint

paper For the primary endpoint, the rate of overall symptomatic hypoglycaemia was not significantly lower with degludec U200 vs glargine U300 (rate ratio [RR] 0.88 [95% CI 0.73, 1.06]). PMID 31984443 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin degludec Protein / enzyme biologic — Subcutaneous
Comparator insulin glargine Protein / enzyme biologic — Subcutaneous